BioSpace News Archive

Orthofix Medical Inc., a leading global spine and orthopedics company, announced that the Company will participate in the Morgan Stanley Healthcare Conference in New York City.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors.

Lantern Pharma Inc. (NASDAQ: LTRN) today announced that it will present positive data highlighting the anti-tumor potency of its drug candidate LP-284 for non-Hodgkin’s lymphoma (NHL) at the Society of Hematologic Oncology (SOHO) Eleventh Annual Meeting occurring on Sept. 6 – 9, 2023, at the George R. Brown Convention Center in Houston, Texas.

Peak Bio, Inc., is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and cancer.

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in September 2023.

Hospital for Special Surgery, the world’s leading academic medical center focused on musculoskeletal health, ranked no. 1 in orthopedics, has expanded its services on Long Island with a new location in Southampton.

Dr. Jaime Schwartz MD, FACS, a distinguished board-certified plastic surgeon and world-renowned specialist in Lipedema, is pioneering a transformative approach to treating this often misunderstood and underdiagnosed fat disorder.

JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25th Annual Global Investment Conference in New York City.

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announced the results of the most comprehensive whole genome sequencing study of Borrelia burgdorferi, the bacteria that causes Lyme disease — a condition affecting nearly 500,000 new patients annually.

Disabling post-COVID symptoms (“long COVID”) and vaccine injury syndromes are increasingly prevalent, and there is no currently accepted treatment protocol, write Peter McCullough, M.D., M.P.H., and colleagues in the fall issue of the Journal of American Physicians and Surgeons.